Summer 2020 - Revolutionizing Natures Medicine for Mental Health & Vitality - Webflow
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Revolutionizing Natures Medicine
for Mental Health & Vitality
Summer 2020
Disclaimer
General
The information provided in this presentation pertaining to Mydecine Innovations Group Inc. ("Mydecine" or the "Company"), its business assets, strategy and operations is for general informational purposes only
and is not a formal offer to sell or a solicitation of an offer to buy any securities, options, futures, or other derivatives related to securities in any jurisdiction and its content is not prescribed by securities laws.
Information contained in this presentation should not be relied upon as advice to buy or sell or hold such securities or as an offer to sell such securities. This presentation does not take into account nor does it
provide any tax, legal or investment advice or opinion regarding the specific investment objectives or financial situation of any person. While the information in this presentation is believed to be accurate and
reliable, Mydecine and its agents, advisors, directors, officers, employees and shareholders make no representation or warranties, expressed or implied, as to the accuracy of such information and Mydecine
expressly disclaims any and all liability that may be based on such information or errors or omissions thereof.
Mydecine reserves the right to amend or replace the information contained herein, in part or entirely, at any time, and undertakes no obligation to provide the recipient with access to the amended information or
to notify the recipient thereof. The information contained in this presentation is intended only for the persons to whom it is transmitted for the purposes of evaluating the Company. The information contained in
this presentation supersedes any prior presentation or conversation concerning the Company. Any information, representations or statements not contained herein shall not be relied upon for any purpose.
Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or
any of your representatives or for omissions from the information in this presentation. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties
in respect of the matters discussed in this presentation.
Confidentiality
This presentation is confidential and is intended, among other things, to present a general outline of the Company. The contents are not to be reproduced or distributed to the public or press.
Each person who has received a copy of this presentation (whether or not such person purchases any securities) is deemed to have agreed: (i) not to reproduce or distribute this presentation, in whole or in part,
without the prior written consent of the Company, other than to legal, tax, financial and other advisors on a need to know basis, (ii) if such person has not purchased securities, to return this presentation to the
Company upon its request, (iii) without the prior written consent of the Company, not to disclose any information contained in this presentation except to the extent that such information was (a) previously known by
such person through a source (other than the Company) not bound by any obligation to keep such information confidential, (b) in the public domain through no fault of such person, or (c) lawfully obtained at a later
date by such persfrom sources (other than the Company) not bound by any obligation to keep such information confidential, and (iv) to be responsible for any disclosure of this presentation, or the information
contained herein, by such person or any of its employees, agents or representatives.
Forward Looking Statements
Certain information set forth in this presentation contains “forward-looking information”, including “future-oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred
to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial
performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures;
(iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) comple-
tion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future
liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so
that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties,
which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking state-
ments will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if
circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Mydecine Innovations Group™ is a publicly traded life sciences parent company dedicated to the development and production of adaptive pathway
medicine, natural health products and digital health solutions. Mydecine’s experienced cross functional teams have the dynamic capabilities to
oversee all areas of medicine development including synthesis, genetic research, import/export, delivery system development, clinical trial execution,
through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military, and clinical organizations,
Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions, and fungtional™ mushroom vitality
products. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm Inc™ focus on providing
innovative and effective options that can provide millions of people with a healthier quality of life.
1
Medicine Evolved
Mydecine™ is a leader in the emerging Fungi and Psychedelic Markets
Across our group of companies, we research, develop
and commercialize a range of innovative mental health and
vitality solutions. TM
✓ PROPRIETARY FORMULATIONS ✓ CLINICAL TRIALS ✓ DIGITAL THERAPEUTICS TM
TM
TM
Mydecine Health Sciences™ is NeuroPharm Inc.™ is
Mindleap Health™ is an
a vertically integrated company responsible for managing
advanced digital telehealth
developing novel fungtional™ clinical trials to develop a
platform that helps people
mushroom vitality products and unique and proprietary set of
connect with mental health
psychedelic medicine to produce pharmaceutical and natural
specialists who can empower
better options for people to live health products addressing
them to thrive and develop
healthier lives. mental wellness in vulnerable
habits for a healthy mind.
populations.
Connected by Vision
1
2
“Mental disorders are on the rise in every country in the
Tackling Mental Health's world and will cost the global economy $16 trillion by 2030”
- Lancet Commission, Oct 10, 2018
Biggest Problems with Our Solutions
450 300 ?
million million 30 %
People suffer from Lacking help and Mental health is lacking data-
of veterans will develop PTSD
mental health issues 100M+ unresponsive driven solutions, especially in
World Wide to treatment specialist contexts
Our Solution: Through our
Our Solution: Create novel Our Solution: Create passive
ecosystem and staff expertise,
Our Solution: Create highly cost effective medicine, and monitoring systems and train
network and partners, we have
scalable treatments including compliment primary offerings predictive models to use these as
the ability to fast track adaptive
digital therapeutics + virtual with affordable mental health proxies for mental health states and
pathway medicine to get the
specialist sessions digital solutions that can be share this information with users
military community the help
accessed from anywhere and mental health specialists.
they need in the fastest way
possible
Connected by Vision
3
Health and Vitality
with Fungtional™ Products
Consumers are shifting away from synthetic chemicals, harmful
supplements, and unhealthy food products, in recognition of increased
health benefits and a better lifestyle.
Our answer: Focus on specialized fungi derived supplements, medicines and
food and beverage products that add incredible benefits into everyone's daily
routine
150 Post
million Pandemic
Americans
45% of the population Our world will be forever changed
have one or more chronic diseases, in the midst of with the advent of Covid 19. People are looking
the most serious pandemic in 100 years. for new solutions to build their immune system
As a result, Americans are searching for healthier and stay healthier by ingesting less synthetic
products more than ever before. food products and consuming more organic
plant based snacks, meals, and drinks to help
their body minimize the growth and spread of
Our Answer: Mydecine is taking a head-first
any disease in their system.
approach into discovering and developing natural
compounds found in fungi, and infusing these into Our Answer: Mydecine is focused on helping
a new category of vitality products people build stronger immune systems by
producing new medicinal fungi-based products.
Connected by Vision
2
4
Global Healing Opportunity Connected by Vision
Fungtional™ Mushroom
Mental Health Problems Virtual Care & Natural Health
300 74 %
of large employer-sponsored health
Global mushroom
million plans had incorporated telehealth
projected market value
people are now living into their benefits as of 2018
with depression -Deloitte CAGR $
86.6 billion
-World Health Organization
8.04 Projection by 2025
- researchandmarkets.com
- Mordor Intellegence
Depression is the leading cause
of ill health and disability
worldwide. 1 of 5 Americans track health
with apps - marketingcharts
Consumers shifting towards natural
and organic products for their health
18 increase
%
57 %
CAGR
$
32.5 billion
between 2005 and 2015
-World Health Organization
of Americans are willing to
receive virtual care. -Deloitte 5.3 Projection by 2019 -2029
-futuremarketinsights
5
Our Revolution in Health Science
Leveraging relationships with scientific, medical, military,
and clinical organizations propelling Mydecine to the forefront of the market.
Mydecine Snapshot Mydecine Team
✓ World-renowned Medical & Scientific Advisory Board ✓ Accomplished entrepreneurs, multiple successful exits.
✓ Schedule 1 Drugs and Substances Dealer’s License through ✓ Proven drug development and approval experience
Health Canada
✓ Over 20 experienced research scientists
✓ Robust clinical trial pipeline, PTSD as initial indication
✓ 30+ years of combined psychedelic industry experience
✓ Deep intellectual property portfolio
✓ 100+ published peer-reviewed studies / papers
✓ State-of-the-art mycology laboratory for genetic R&D
✓ World-class team drawn from Pfizer, Novartis, Yale, Imperial
✓ Unparalleled global relationships with veteran organizations College, and Canadian, US and EU Militaries
✓ Launching an advanced digital telehealth platform
✓ Introducing new lines of consumer based fungtional™
mushroom vitality products
1
6
The Ecosystem of Mydecine
t
Cultivating rare and unique fungi varietals
Growing + Processing
Fungi for clinical research and for fungtional™ Growing + Processing
health and vitality products Fungi
Extracting + Isolating Developing novel processing techniques
Active Compounds and using them to efficiently process and
prepare active fungal compounds
Connecting
Patients to Digital Care, Extracting + Isolating
From Anywhere Active Compounds
Researching + Testing Robust R+D pipeline, via partnerships
Novel Medicines with leading universities across the globe
Distributing across North America
Global Distribution and other regions of the globe
with our established partners and affiliates
Researching + Testing
Global Distribution Novel Medicines
Connecting
Patients to Digital Care, Virtual therapeutic programs, advanced tracking,
From Anywhere digital mental healthcare via Mindleap Health
Connected by Vision
7
Connected by Vision
5. Leverage our data
to develop new products,
services, and targeted
therapies
4. Capture and learn Using this data with integrity
from vast, high fidelity and responsibility, we are able
data sets to train advanced deep
3. Digitize healthcare learning models that use
Across all our operations artificial intelligence to make
to improve global & we are developing novel,
remote access predictions around
high-fidelity data sets, therapeutics, treatments,
Our advanced digital health thereby developing a deep genomics, mental health,
2. Conduct clinical trials to platform helps people understanding and industry- and user behavior, in order
demonstrate their efficacy connect with mental health leading models of genomics, to personalize healthcare like
specialists and digital pharmacology, synthetic never before.
Through our Neuropharm and biology, mycology, virtual
therapeutic programs that
Mydecine Health Sciences™ therapy, psychedelics, and
1. Discover new medicines, research teams, we are conducting
empower them to thrive and
therapies, and natural products develop habits for a healthy mental health.
clinical trails and research in order
mind.
Our research teams are exploring to commercialize novel fungi and
rare and novel compounds and their psychedelic based therapies and
uses with fungtional™ mushroom treatments.
vitality products and psychedelic
fungi medicine.
8TM
Strategy
Two complimentary business lines bound by common fungi-based science
Therapeutic Medicine Consumer Products
✓Therapeutics addressing a range of ✓Fungi-infused products for
mental health conditions the consumer market
• Proprietary psilocybin dosage control • Proprietary fungi infused goods starting
delivery technologies, improving medicine with coffee and chocolate product lines
bioavailability, and increasing absorption launching Q4 2020
• Controlling time and potency • Partnership with one of the world’s largest
enabling sub perceptual "micro" dosage premium coffee and chocolate producers
forms
• Access to a broad array of mycology compounds, • 46,000 sq. ft. manufacturing
and distribution center
rare, naturally sourced psilocybin producing
mushrooms
• Fully-integrated, spore-to-sale™ -
research, development,
• Addressing a range of mental health conditions now manufacturing and distribution
treated with anxiolytics and/or anti-depressants
Connected by Vision
9
9TM
Assets & Partners
Mydecine Center of Mycology
Mydecine Center of Mycology
Laboratory & US Headsquarters ✓ 7500 sq. ft state-of-the-art mycology lab
Denver, Colorado, USA ✓ Genetic research, IP, product development
✓ Production of all fungi medicinal compounds
✓ Analytical chemistry, genomics, tissue culture
✓ GMP-compliant SOP production processes
Alternative Distribution Company
D I S T R I B U T I O N C O M P A N Y™
Dallas, Texas, USA ✓ Alternative Distribution Company is an innovative new distribution company focusing on emerging products
✓ Made up of industry veterans who understand regulated distribution and the value of a pre-regulation vertically
50% stake in Alternative Distribution Company to integrated path to market
support nation-wide distribution and manufacturing ✓ Relationships with 10's of thousands of retail outlets including HEB, Costco, Whole Foods, Kroger and more
✓ Leveraging infrastructure from one of Texas’ largest spirit and wine distribution companies with sales in excess
of $50M
✓ Creating vertical integration or true partnerships with growers, producers, brands, end users and retailers
✓ Responsible for building/creating some of the worlds largest beverage and consumer facing brands today
Connected by Vision 10TM
Assets & Partners
Our partnership with API and the University of Alberta, enables MHS to field
unparalleled studies with precise control over study design and drug format.
We plan to utilize this both for our own work and to further
collaboration with academic leaders in the field.
✓ Health Canada Scheduled 1 Drugs and Substances Dealer’s License
✓ 30 + Ph.D.’s, scientists, clinicians, regulatory, patent experts
✓ Drug Design, target discover, validation
✓ Analytical testing, performance characterization
✓ Medicinal chemistry and synthesis
✓ School of Pharmacy recognized expertise
✓ Ensures clinical study drug supply, all schedule classes
✓ Cultivation of psilocybin producing mushrooms
✓ Access to hospital network for enablement of clinical research
✓ Ability to cultivate, extract, conduct R&D, import and export full cGMP certified
pharmaceutical grade natural and synthetic psilocybin and other tryptamines
Connected by Vision
11Fully connected
Normal functioning brainwave activity during a
brainwave network therapeutic psilocybin / psilocin
psychedelic experience
Strategy
Developing innovative psilocybin therapies to treat a range of
mental conditions in the Veteran community
Singular focus on Veteran health and wellness, Unmatched associations with clinical,
PTSD as initial indication academic and research institutions
®
Robust clinical trial calendar across multiple World-class SAB, thought leaders across
global sites multiple disciplines
Industry-leading mental health
$
professionals, decades of treatment Proven ability to source non-dilutive funding,
experience, both traditional and $100+million
innovative
Connected by Vision
12Clinical Trial Program Global Military Relationships
• 7 + clinical trials
Canada, US, EU addressing PTSD • Canadian Armed Forces
in Veterans commenced Q3 2020
• US Military
• Virtual Reality augmented psilocybin
clinical trial slated for 2021 • Armed forces of the Netherlands
• British Military
• Australian Military
Global Alliances Veterans Organizations
• Leden University, The Netherlands ✓Wounded Warriors
• McMaster University ✓Heroic Hearts
• University of Western Ontario ✓True Patriot Love
• New York University • Co-promotional programs
• University of Southern California • Veteran mental health and wellness
• Mt. Sinai Hospital
• The Royal Ottawa Hospital Connected by Vision
13Strategy
Mindleap is the first-to-market digital health platform that combines telehealth with mood,
emotion and habit tracking. This is a paradigm shift to conventional mental health as
it provides personalized support and the tools needed to provide data driven insights into
each individuals mental health.
First mover in rapidly emerging Provides critical tools to expand patient access
psychedelic therapy sector and improve treatment outcomes
Offers automated scheduling, billing, analytics and
$
Strong Revenue Model with two revenue
confidential HIPAA compliant video mental health
streams: PAAS, Digital Products
sessions
The global telemedicine market is booming
Innovative technology with strong USP and
and will expand from its current $38.3
large addressable market
billion valuation to $130.5 billion by 2025
Connected by Vision
14Intelligent systems built to sense mental health states to
maximize the treatment outcomes
Collect application usage metrics along
with social phone utilization metrics like
calls and texts.
Collect routine data like sleep,
movement and exercise Phone
Utilization Analyze data with
machine learning.
Activity Patterns AI Analysis
Predict user state and
Connect to wearables to track daily
behavior to optimize support
activity and biometric information.
and predict best treatment
response.
Wearables Define State
• Digital Phenotyping • Clinically viable solutions first
Mindleap will be monitoring how a user interacts with their Mindleap will begin collecting its initial dataset through the launch
smartphone using an artificial intelligence machine learning of the platform and will launch passive data tracking features once
data model to make accurate predictions about mental health platform launches.
state.
• User privacy and security
• Research backed methodologies Mindleap is committed to preserving the privacy and confidentiality
Over the past two decades, research on digital phenotyping of users and will not sell or license any data.
for mental health has been increasing, offering substantial
insight into optimal methodologies, research goals, and Connected by Vision
patient outcomes. 15Developing novel fungtional™
Mydecine Itself is a mushroom products
and psychedelic medicine.
Fungtional™ Network
TM
Unlimiting our research with exclusive
Data Collection
permission to import, export, and study
scheduled compounds
Data to predict new prospective
candidate treatments
R&D
+ Clinical Trials
Mydecine Center of Mycology
Laboratory & US Headsquarters
Denver, Colorado, USA
Fast-tracking our research
with research design support
+ military relationships
Direct access to veterans
and military personnel
at highest levels
Mental Health
Veterans Organizations
Connected by Vision
1
16Market Comparison
Possess a Schedule 1 Substances and Drugs
Dealer’s License to legally research psilocybin NO NO NO
Able to import / export whole mushrooms
containing psilocybin NO NO NO
Have direct cGMP lab access for R&D NO NO NO
Have direct access to a virtual telehealth
app for psychedelic after-care NO NO NO NO
remote therapy
Collaborating with Military personnel NO NO NO NO
Developing and producing non-psychedelic
fungtional™ mushroom products for NO NO
the retail market
Have a dedicated state-of-the-art NO NO NO
mycology lab
NO
Developing IP for patent filings
Researching psilocybin for PTSD,
Addiction, Depression, Anxiety, NO NO NO NO
and headaches
Studying mushroom genome sequencing NO NO NO NO
Using high-grade nanotechnology compound
delivery mechanisms for increased NO NO
bioavailability
Clinical Trials - Clinical Trials - Clinical Trials - Clinical Trials -
Stage of clinical trials Preclinical Phase 1
Phase 1 Phase 2 Phase 2
171Connected by Vision
Company Milestones Evolution Clinical Trials Patent Filings
(July 14th)
Signed Definitive
Agreement with NeuroPharm
adding valuable intellectual property and
novel psychedelic medicine ready to go into World’s first cGMP pharmaceutical
clinical trials to focus on PTSD in veterans
grade fungal derived psilocybin sold and
exported to leading research institution
Established a R&D partnership with
Applied Pharmaceutical Innovation
through the faculty of drug discovery and pharmaceutical Launch Mindleap platform
medicine out of the University of Alberta sessions start happening on platform
6th Clinical Trial
Capital Raise - (May 7th) 1st Clinical Trial
Leiden University 4th Clinical Trial 8th Clinical Trial
Non-Brokered closed Launch digital programs
Psilocybin assisted Psychotherapy 3rd Clinical Trial
for $2,645,421 in PTSD / Veterans ( Dr. Eric Vermetten) on Mindleap Platform
Company MARCH - AUGUST 2020 SEPT - OCT 2020 NOV - DEC 2020 Q2 - 2021
Founded
2nd Clinical Trial Launch Digital
(August 21st)
5th Clinical Trial 7th Clinical Trial Phenotyping on
Acquired Mindleap Health Launch of initial
Built out a 7,500 sq. ft. Mindleap Platform
advanced digital wellness, therapeutic, natural health SKUs
state-of-the-art and psychedelic integration platform
mycology laboratory in including mental health data capture
4th Patent Filing
Denver, Colorado 1st Patent Filing 2nd Patent Filing
First rare species of 3rd Patent Filing
Capital Raise - (June 9th) psilocybin producing mushrooms
Cannacord Brokered for gross arrive onsite at U of A
proceeds of $2,400,000 18Key Personnel
TM
Joshua Bartch, Director, CEO & Co-Founder James Gunning, CMO Colonel (Ret’d) Richard Pucci, OMM, CD, BSc, MDS COL Dr. Mohyuddin Mirza, Ph.D., P.Ag Nikolai Vassev, Founder
David Joshua Bartch is Director, President & CEO of Mydecine Jim Gunning is the CMO of Mydecine Innovations Group. Mr. (Ret’d) Pucci served in many command and strategic level Dr. Mirza is a botanist who brings over four decades of Strong track record with high-growth tech companies,
Innovations Group. Mr. Bartch's entrepreneurial career took off in Gunning has significant experience in senior marketing and forming multi-million-dollar partnerships, leading complex
staff positions on behalf of the Canadian Forces in Canada, experience and industry knowledge to greenhouse
2009 when he co-founded AudioTranscriptionist.com and founded leadership roles. He was one of the first hires at Red Bull North data analytics and cyber security software projects for
the United Kingdom, United States, and operational tours. He technologies. Dr. Mirza holds a Ph.D. from the University of
the Denver based dispensary, Doctors Orders. Following these America. In his 10 years with the brand he had a significant role in various Fortune 500 organizations, as well as for the US
retired at the rank of Colonel while serving as the Deputy Alberta and served as an adjunct professor at his alma
ventures, Mr. Bartch founded a boutique investment firm that their success as a Director of Marketing in their HQ office. He has
Commander of the Canadian Forces Health Services. As matter. Dr. Mirza was inducted into the Alberta Agriculture and Canadian Governments.
operated throughout the U.S. and Canadian markets. In 2014, since worked with several other major brands developing
Deputy Commander, Col. Pucci oversaw a team of Hall of Fame and subsequently the Alberta Greenhouse Rafal Osowicki, Software Architect
Bartch co-founded Cannabase.io, the USA's most significant legal significant strategic marketing and partnership initiatives and has
worked with multiple start ups. approximately 6,400 active members and 500 contractors; Growers Association created the Dr. Mohyuddin Mirza Seasoned Technology Director - Has led large technical
and sophisticated cannabis wholesale platform. In 2015,
Cannabase.io was acquired by Helix TCS.
responsible for overwatch via the chain of command of 43 Educational and Scholarship Foundation. Dr. Mirza has teams encompassing complex software development
Michael Connolly, J.D., CCO units and 82 detachments, incl. clinics, mobile medical units, consulted with agencies in all sectors. He brings vast projects. Over 10 years of industry experience
Damon Michaels, Director, COO & Co-Founder Michael Connolly is the Chief Compliance Officer and General field hospital, schools, research establishment, and medical knowledge of greenhouse technologies, infrastructure,
Damon Michaels is the Chief Operations Officer of Mydecine Simon Abou-Antoun, MBA, BE,
Counsel for Mydecine Innovations Group. He has a 28-year equipment depot. Served as Chief of Staff of the Health feasibility, R&D
Innovations Group. Prior to joining MIG, Mr. Michaels was consulting extensive background in corporate law, finance, and transactional 10+ years of technical leadership, running teams and
Services Group, with the overall responsibility for a financial
for various hemp businesses through his company, Emerald Baron.
law, as well as commercial litigation. Mr. Connolly has served as Dr. Zul Merali, Ph.D. developing custom solutions for companies including
and business planning cycle of $462 million, and infrastructure
Before that, he served as GM for the leading multi-platform Dr. Zul Merali was President/CEO and Scientific Director Amazon, Scotia Bank and Fiat Chrysler.
counsel and advisor for numerous start-up companies, including
budget of $600 million.
cannabinoid research and technology firm based in Colorado of the University of Ottawa Institute of Mental Health
companies in the cannabis and CBD industries. He has been Tomasz Dzieniak - Mobile App Development lead
called ebbu. In November of 2018, ebbu was acquired for
responsible for managing complex financial transactions, Dr. Rakesh Jetly, OMM, CD, MD, FRCPC Research. He was also full professor in the faculties of Highly skilled and thoroughly experienced mobile app
CAD$429m by Canopy Growth for being the cutting edge leader in
compliance and regulatory matters, and investor relations. Juris Dr. Jetly is currently the Head of the Centre of Excellence on Mental Medicine (Departments of Cellular and Molecular development professional. With over 11 years of
cannabinoid science. Over the last decade, Mr. Michaels has been
Doctorate from Creighton University School of Law and is licensed Health in Ottawa, Ontario, and an associate professor of psychiatry Medicine and Psychiatry) and Social Sciences programming experience and more than 100 completed
in leading roles with multiple large brands throughout the cannabis
to practice law in Colorado, Florida, and Nebraska. at Dalhousie University (Halifax), and the University of Ottawa. He (Psychology) at the University of Ottawa, as well as projects he has experience leading iOS and Android
vertical in Colorado and California. Outside of the cannabis industry,
has published numerous articles in professional journals and research professor at the Institute of Neuroscience at
teams, realizing complex and demanding projects and
he developed a national snowboard brand with his team, was one Cynthia Salarizadeh, PR presents nationally and internationally on such topics as post- Carleton University. Dr. Merali's research focuses on the
solving API related issues.
of four entrepreneurs who created Colorado’s first-ever glass
Cynthia Salarizadeh is the head of public relations for Mydecine traumatic stress disorder and operational psychiatry. Dr. Jetly has body's response to stressful and appetitive events as well
recycling company, and was on the business development team for Jack Bunce, Marketing and Operations
Innovations Group. She has more than 20 years experience in previously held various professional positions as a psychiatrist, as how pharmacological interventions may attenuate
a Google Ventures Company. Marketing and AI Expert - Launched Triage.com, the
strategic communications and mass media relations. Cynthia is including: Director of the “Operational Trauma and Stress Support stress-induced pathophysiology. Dr. Merali's research
the founder of the newswire and entrepreneur tech suite, AxisWire, world's first and largest predictive AI Dermatology Platform,
Robert Roscow, MA, CSO & Co-Founder Centre,” Atlantic Region (2000-2008); Chief Resident in Psychiatry, investigations also extend from the behavioral to the
developed and led marketing projects for multinational
Robert Roscow is the Chief Scientific Officer of Mydecine as well as the luxury brand House of Saka. She is also the Co- ͘ Michael’s Hospital (1999-2000); and Senior Medical Officer for
St cellular and molecular levels and involve experimental
Innovations Group. As a highly educated geneticist, he has spent banks, consumer rewards, and technology companies
founder of cannabis finance news publication Green Market Report. the “Canadian Contingent United Nations Middle East” in Israel animals as well as human subjects. Dr. Merali has
his academic and professional careers looking for valuable and KCSA Strategic Communications acquired her leading cannabis (1993-1994). published over a hundred scientific papers, more than 20
unique medicinal molecules found in nature. The last two
and hemp public relations firm Salar Media Group. book chapters and over 100 conference presentations.
companies that Robert applied his innovations to were Canopy
Growth and ebbu where he ran their genetics divisions. Mr. Roscow
has already leveraged an expertise in genomics, evolution and
molecular biology to maximize the industrial production of
cannabinoids and their use in a pharmacological context.This work
has resulted in multiple patent filings and accolades in publications
ranging from Nature to Rolling Stone. Now, Mr. Roscow has set his
Connected by Vision
focus on the vast healing potential of fungi. 1
19TM
Medical and Scientific Advisors
Rick Barnett Psy.D., MA, MS, LADC Eric Vermetten, Prof. dr. H.G.J.M. MD, Ph.D. Colonel Ruth Lanius, MD, Ph.D. David Erritzoe, MD, Ph.D., MRCPsych
Clinical psychologist who is an expert in addictive disorders Dr. Vermetten is professor of Medical-Biological and Professor of Psychiatry is the director of the post-traumatic NIHR Academic Clinical Lecturer in General
(including sex, drugs and food addiction) and problems such Psychiatric Aspects of Psychotrauma, LUMC/University stress disorder (PTSD) research unit at Western University. Psychiatry in Neuropsychopharmacology and
as depression, anxiety, and relationship difficulties. Rick has Established the Traumatic Stress Service and the Traumatic Psychedelic Research Centres, Division of
of Leiden. The chair was established by Arq
experience in a range of approaches to treating problems Stress Service Workplace Program, services that specialize in Psychiatry, Dpt of Brain Sciences, Imperial
Psychotrauma Research and the Dutch Ministry of
related to addictive behaviors.
Defense. Eric Vermetten is an active clinical psychiatrist the treatment and research of PTSD. College London.
Danielle Wise, Ph.D. at the MGGZ in Utrecht (Military Mental Health care).
Vince Polito, Ph.D.
From 1991 he has been linked to several universities as Robin Carhart-Harris, Ph.D.
30 years of psychotherapy, mental health coaching, Cognitive Science Researcher at Macquarie
a researcher, including Stanford University, California, Leads Imperial College London’s Centre For Psychedelic
and therapy work with thousands of clients. Significant
Yale Univ, New Haven CT, Emory Univ, Atlanta, and University, Australia with significant
experience in psychedelic aftercare and utilizing Research. Regularly publishes research on psychedelic
studied at the University of Maastricht and followed experience in psilocybin microdosing
telemedicine tools in her practice. medicines in clinical perspectives.
several postgraduate courses. research. In 2019 led & conducted one of the
Margaret McKinnon Ph.D., CPSYCH
largest to date systematic study of
Dr. Vermetten has published over 300 articles and Carl Castro
microdosing psychedelics.
Dr. McKinnon received her Ph.D. in Psychology from the book chapters on topics ranging from large Carl Castro is the research director for the USC Center for
University of Toronto in 2003 and subsequently completed longitudinal studies following soldiers’ deployments to Innovation and Research on Veterans and Military Families. Anton Gomez-Escolar, MA, MSc
her postdoctoral fellowship at the Rotman Research Institute. innovative approaches to treatment. He continues to Castro has served in a variety of research and leadership Psychopharmacologist, a Member of the
She holds or has held competitive grant funding from the be a leader within the international psych traumatology positions, including commander of the U.S. Army Medical UNAD commission on international drug
Bickell Foundation, Canadian Institutes of Health Research, community within NATO and beyond. Research Unit-Europe in Heidelberg, Germany; chief of the policy. Advisor to large pharma and
Canadian Institute for Military and Veteran’s Health Research,
the National Institute for Mental Health, N RS D, and OMHF.
Department of Military Psychiatry at the Walter Reed Army nutraceutical companies, investment firms,
Denton Hoyer, Ph.D.
Institute of Research in Washington, D.C.; and director of the and government committees on public health.
Dr. Hoyer has been involved in drug discovery at leading Military Operational Medicine Research Program,
Gary H. Wynn, MD, COL, MC, USA
pharmaceutical companies and research institutions for Headquarters, U.S. Army Medical Research and Materiel
Dr. Gary Wynn is Professor of Psychiatry and Neuroscience,
the last 30 years. He holds numerous patents and has Command, Fort Detrick, Md.
Assistant Chair of the Department of Psychiatry, and Senior
been published extensively in the field of medicinal
Scientist at the Center for the Study of Traumatic Stress. He is also Castro has authored more than 150 scientific articles and
a Distinguished Fellow of the American Psychiatric Association and
chemistry and drug research. Dr. Hoyer has unparalleled
reports in numerous research areas and currently serves as
on the editorial board of the Journal of Neuroscience Research. expertise in computational chemistry enabled probe
chair of a NATO research group on military mental health
Dr. Wynn received his education at the United States Military molecule design, drug design and optimization, synthetic
training. He serves as an advisor for several Department of
Academy at West Point and Uniformed Services University of the planning and execution, evaluation of chemical novelty
Defense research panels focused on psychological health.
Health Sciences. and intellectual property assessment and strategies.
Paul Frewen, MD Ph.D.
Rachel Yehuda, Ph.D. Malireddy Srinivasulu Reddy, Ph.D.
Dr. Frewen joined the departments of psychiatry and
Professor of Psychiatry and Neuroscience, is the Director of As a 7-time Nobel Peace Prize Nominee, Dr. Reddy is the psychology at the University of Western Ontario in London,
the Traumatic Stress Studies Division at the Mount Sinai
founder and president of Denver-based American Dairy Ontario, Canada in September 2008. He completed his
School of Medicine which includes the PTSD clinical
and Food Consulting Laboratories and International doctorate in clinical psychology at Western and his post-
research program and the Neurochemistry and
Neuroendocrinology laboratory at the James J. Peters
Media and Cultures (IMAC Inc.). He holds over 150 U.S. doctoral residency at the Royal Ottawa Mental Health Centre.
Veterans Affairs Medical Center. She received her PhD in and international patents and has published over 80 He has chaired the Traumatic Stress Section of the Canadian
Psychology and Neurochemistry and her MS in Biological scientific articles on dairy starter cultures, probiotics, Psychological Association (CPA) and is current chair of the
Psychology from the University of Massachusetts at Amherst pharmaceuticals, and complementary alternative practice committee of the American Psychological Association
and completed her postdoctoral training in Biological medicines pertaining to probiotics. (APA) Psychological Trauma Division. Connected by Vision
Psychiatry in the Psychiatry Department at Yale Medical
20
1
School.Mydecine Innovations Group Inc. ( MYCO) .50
Financial Highlights
Issued & Outstanding
146,081,159
Reserved for Issuance
5,086,157
Symbol / Trading Market :
( CSE: MYCO ) (OTC : MYCOF ) ( FSE : 0NFA )
Total I/O Warrants : 1,743,000
Total I/O Options : 3,343,157
52 - week - High and Low : 1.15 - 0.04
Average Daily Trading Volume : 552.68K
Market Cap : 71.58M
Status: Active Connected by Vision
Industry : Life Sciences
21direct ac
and mil
at h
Men
Veterans
The Mydecine Advantage unlimiting our research with exclusive
permission to import, export, and study
scheduled compounds
R+D
Clinical Trials
✓ A leader in the emerging psychedelic health and fungtional™ vitality
product markets fast-tracking our research
with research design support
+ military relationships
✓ Sophisticated domestic and international partnerships
✓ Multiple, complementary initiatives leveraging psilocybin based deve
and
science and technologies
Launch digital programs Launch Digital Phenotyping
Launch Mindleap platform on Mindleap Platform on Mindleap Platform
✓ Management team with track record of multiple successful exits sessions start happening on platform
SEPT - 2020 NOV - 2020 DEC - 2020 Q2 - 2021
✓ Robust clinical pipeline across a range of global sites
✓ Uniquely positioned to address large unmet needs, Launch of initial natural health SKUs
such as Veteran PTSD
✓ Unparalleled access to Veteran organizations and military
establishments
✓ World-renowned SAB, thought-leaders spanning multiple disciplines
✓ Established record of sourcing non-dilutive funding – DARPA, DoD,
philanthropic
✓ Well-defined 18-month value inflection trajectory and news flow
Connected by Vision
2220Josh Bartch, CEO / Damon Michaels, COO
corp@mydecineinc.com
www.mydecine.com
THANK YOU.
Founded March 2020
USA Office Canada Office
1250 S. Parker Rd. 789 W Pender St.
Lower Level, Suite A Suite 810
Denver, CO 80231 Vancouver, BC V6C 1H2
@mydecineinc @mydecineig @mydecineig @mydecineYou can also read
